Global Metabolic Syndrome Market Size, Status, Research and Forecast 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 105

Report ID: 3638

Metabolic syndrome is a cluster of conditions — increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels — that occur together, increasing your risk of heart disease, stroke and diabetes.
One of the upcoming trends gaining traction in the market is the increasing focus on oral insulin therapies. Till now, insulin injections were mostly administered through subcutaneous tissues, but this route of application is associated with risk of infection and hypersensitivity reactions, emboli, high cost, and injection site pain. Also, several needle-phobic individuals hesitate to adopt this route of administration. This paved the way for extensive research in the development of oral insulin. The oral form of insulin prevents the unpleasantness of insulin injections and other complications associated with the existing therapies. Moreover, oral administration of insulin ensures increased patient comfort and compliance, reduced risk of infection, simpler application, and is cost-effective.
In 2018, the global Metabolic Syndrome market size was 24600 million US$ and it is expected to reach 36700 million US$ by the end of 2025, with a CAGR of 5.1% during 2019-2025.

This report focuses on the global Metabolic Syndrome status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Metabolic Syndrome development in United States, Europe and China.

The key players covered in this study
Novo Nordisk
Sanofi
Merck
AstraZeneca
Eli Lily
AbbVie
Actelion Pharmaceuticals
Adocia
Aegerion Pharmaceuticals
Akros Pharma
Alnylam Pharmaceuticals
Amarin
nAmgen
Amicus Therapeutics
Arbutus Biopharma

Market segment by Type, the product can be split into
Diabetes
Obesity
Hypercholesterolemia
Lysosomal storage diseases

Market segment by Application, split into
Hospital
Clinic
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Metabolic Syndrome status, future forecast, growth opportunity, key market and key players.
To present the Metabolic Syndrome development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Metabolic Syndrome are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Metabolic Syndrome Market Size Growth Rate by Type (2014-2025)
1.4.2 Diabetes
1.4.3 Obesity
1.4.4 Hypercholesterolemia
1.4.5 Lysosomal storage diseases
1.5 Market by Application
1.5.1 Global Metabolic Syndrome Market Share by Application (2014-2025)
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Metabolic Syndrome Market Size
2.2 Metabolic Syndrome Growth Trends by Regions
2.2.1 Metabolic Syndrome Market Size by Regions (2014-2025)
2.2.2 Metabolic Syndrome Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Metabolic Syndrome Market Size by Manufacturers
3.1.1 Global Metabolic Syndrome Revenue by Manufacturers (2014-2019)
3.1.2 Global Metabolic Syndrome Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Metabolic Syndrome Market Concentration Ratio (CR5 and HHI)
3.2 Metabolic Syndrome Key Players Head office and Area Served
3.3 Key Players Metabolic Syndrome Product/Solution/Service
3.4 Date of Enter into Metabolic Syndrome Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Metabolic Syndrome Market Size by Type (2014-2019)
4.2 Global Metabolic Syndrome Market Size by Application (2014-2019)

5 United States
5.1 United States Metabolic Syndrome Market Size (2014-2019)
5.2 Metabolic Syndrome Key Players in United States
5.3 United States Metabolic Syndrome Market Size by Type
5.4 United States Metabolic Syndrome Market Size by Application

6 Europe
6.1 Europe Metabolic Syndrome Market Size (2014-2019)
6.2 Metabolic Syndrome Key Players in Europe
6.3 Europe Metabolic Syndrome Market Size by Type
6.4 Europe Metabolic Syndrome Market Size by Application

7 China
7.1 China Metabolic Syndrome Market Size (2014-2019)
7.2 Metabolic Syndrome Key Players in China
7.3 China Metabolic Syndrome Market Size by Type
7.4 China Metabolic Syndrome Market Size by Application

8 Japan
8.1 Japan Metabolic Syndrome Market Size (2014-2019)
8.2 Metabolic Syndrome Key Players in Japan
8.3 Japan Metabolic Syndrome Market Size by Type
8.4 Japan Metabolic Syndrome Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Metabolic Syndrome Market Size (2014-2019)
9.2 Metabolic Syndrome Key Players in Southeast Asia
9.3 Southeast Asia Metabolic Syndrome Market Size by Type
9.4 Southeast Asia Metabolic Syndrome Market Size by Application

10 India
10.1 India Metabolic Syndrome Market Size (2014-2019)
10.2 Metabolic Syndrome Key Players in India
10.3 India Metabolic Syndrome Market Size by Type
10.4 India Metabolic Syndrome Market Size by Application

11 Central & South America
11.1 Central & South America Metabolic Syndrome Market Size (2014-2019)
11.2 Metabolic Syndrome Key Players in Central & South America
11.3 Central & South America Metabolic Syndrome Market Size by Type
11.4 Central & South America Metabolic Syndrome Market Size by Application

12 International Players Profiles
12.1 Novo Nordisk
12.1.1 Novo Nordisk Company Details
12.1.2 Company Description and Business Overview
12.1.3 Metabolic Syndrome Introduction
12.1.4 Novo Nordisk Revenue in Metabolic Syndrome Business (2014-2019)
12.1.5 Novo Nordisk Recent Development
12.2 Sanofi
12.2.1 Sanofi Company Details
12.2.2 Company Description and Business Overview
12.2.3 Metabolic Syndrome Introduction
12.2.4 Sanofi Revenue in Metabolic Syndrome Business (2014-2019)
12.2.5 Sanofi Recent Development
12.3 Merck
12.3.1 Merck Company Details
12.3.2 Company Description and Business Overview
12.3.3 Metabolic Syndrome Introduction
12.3.4 Merck Revenue in Metabolic Syndrome Business (2014-2019)
12.3.5 Merck Recent Development
12.4 AstraZeneca
12.4.1 AstraZeneca Company Details
12.4.2 Company Description and Business Overview
12.4.3 Metabolic Syndrome Introduction
12.4.4 AstraZeneca Revenue in Metabolic Syndrome Business (2014-2019)
12.4.5 AstraZeneca Recent Development
12.5 Eli Lily
12.5.1 Eli Lily Company Details
12.5.2 Company Description and Business Overview
12.5.3 Metabolic Syndrome Introduction
12.5.4 Eli Lily Revenue in Metabolic Syndrome Business (2014-2019)
12.5.5 Eli Lily Recent Development
12.6 AbbVie
12.6.1 AbbVie Company Details
12.6.2 Company Description and Business Overview
12.6.3 Metabolic Syndrome Introduction
12.6.4 AbbVie Revenue in Metabolic Syndrome Business (2014-2019)
12.6.5 AbbVie Recent Development
12.7 Actelion Pharmaceuticals
12.7.1 Actelion Pharmaceuticals Company Details
12.7.2 Company Description and Business Overview
12.7.3 Metabolic Syndrome Introduction
12.7.4 Actelion Pharmaceuticals Revenue in Metabolic Syndrome Business (2014-2019)
12.7.5 Actelion Pharmaceuticals Recent Development
12.8 Adocia
12.8.1 Adocia Company Details
12.8.2 Company Description and Business Overview
12.8.3 Metabolic Syndrome Introduction
12.8.4 Adocia Revenue in Metabolic Syndrome Business (2014-2019)
12.8.5 Adocia Recent Development
12.9 Aegerion Pharmaceuticals
12.9.1 Aegerion Pharmaceuticals Company Details
12.9.2 Company Description and Business Overview
12.9.3 Metabolic Syndrome Introduction
12.9.4 Aegerion Pharmaceuticals Revenue in Metabolic Syndrome Business (2014-2019)
12.9.5 Aegerion Pharmaceuticals Recent Development
12.10 Akros Pharma
12.10.1 Akros Pharma Company Details
12.10.2 Company Description and Business Overview
12.10.3 Metabolic Syndrome Introduction
12.10.4 Akros Pharma Revenue in Metabolic Syndrome Business (2014-2019)
12.10.5 Akros Pharma Recent Development
12.11 Alnylam Pharmaceuticals
12.12 Amarin
12.13 nAmgen
12.14 Amicus Therapeutics
12.15 Arbutus Biopharma

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details